CTRI/2011/07/001856Other4 期
A single center, randomized, double-blind study to assess the efficacy and safety of fixed dose 1.5 % Aminexil and 5 % Minoxidil topical solution vs 5 % Minoxidil topical solution in male pattern hair loss
Glenmark Pharmaceuticals Ltd0 个研究点目标入组 40 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- Other
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Male patients of age more than 18 to 50.
- •Presence of androgenetic alopecia based on the Norwood Hamilton Scale
- •Written informed consent by patient.
- •Patient willing to follow up.
排除标准
- •Alopecia areata, alopecia totalis, alopecia universalis and alopecia diffusa.
- •Scarring of the scalp or any other condition or disease of the scalp or hair, including diseases of the hair shaft and inability to discontinue use of hair weaving.
- •Use of the following during the 6 months prior to screening:
- •?XMinoxidil (oral or topical)
- •?XDrugs with anti-androgenic properties (e.g., cyproterone acetate, spironolactone, ketoconazole, flutamide, bicalutamide). Cimetidine cannot be used during the study but is not an excluded drug when used during the previous 6 months.
- •?XDrugs potentially causing hypertrichosis (e.g., cyclosporine, diazoxide, phenytoin psoralens)
- •?XAnabolic steroids
- •?XLithium and phenothiazines
- •Use of systemic steroids for more than 14 days within the past 2 months prior to enrollment in the study.
- •Use of isotretinoin, radiation to the scalp, or chemotherapy within the past year.
- •Known sensitivity to the investigational product
研究者
相似试验
已完成
4 期
The efficacy of Prontoderm® for topical decolonisation of methicillin-resistant Staphylococcus aureus (MRSA) carriersISRCTN02288276Geneva University Hospitals (Hôpitaux Universitaires de Genève) (Switzerland)160
进行中（未招募）
不适用
A Single Centre, Double-blind, Randomised Study To Investigate a Single Oral Dose of IMD-1041 in A Nasal Allergen Challenge (NAC) ModelIt is intended to investigate the potential therapeutic benefit of IKKß inhibition in man by oral dosing of IMD-1041 in a Nasal Alllergen Challenge.MedDRA version: 14.1Level: PTClassification code 10053467Term: Antiinflammatory therapySystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2007-000190-28-GBInstitute of Medicinal Molecular Design Inc12
Unknown
3 期
A Randomized, Double Blind, Single Centre, study to assess the efficacy, safety and tolerability of the Gastrin Receptor Antagonist (GRA), Netazepide administered for 90 days, in post-menopausal women (OSTEO-GRA)PACTR202407466904092niversity of Cape Town90
进行中（未招募）
不适用
A double-blind, randomized, multi-center study to investigate the endometrial safety of a continuous, combined, oral estrogen/progestin preparation (0.5 mg 17b-estradiol [E2] / 0.25 mg drospirenone [DRSP]) and to compare the bleeding pattern of subjects treated with 0.5 mg E2 / 0.25 mg DRSP with the bleeding pattern of subjects treated with 1.0 mg E2 / 0.5 mg norethisterone acetate (NETA) when used for hormone therapy (HT) for 1 year in post-menopausal women - Angeliq low/low endometrial safety studyEUCTR2006-006199-39-ATBayer Schering Pharma AG600
进行中（未招募）
不适用
A double-blind, randomized, multi-center study to investigate the endometrial safety of a continuous, combined, oral estrogen/progestin preparation (0.5 mg 17b-estradiol [E2] / 0.25 mg drospirenone [DRSP]) and to compare the bleeding pattern of subjects treated with 0.5 mg E2 / 0.25 mg DRSP with the bleeding pattern of subjects treated with 1.0 mg E2 / 0.5 mg norethisterone acetate (NETA) when used for hormone therapy (HT) for 1 year in post-menopausal women - Angeliq low/low endometrial safety studyWomen suffering from postmenopausal symptomsMedDRA version: 9.1Level: LLTClassification code 10050903Term: Postmenopausal symptomsEUCTR2006-006199-39-DKBayer AB, Bayer Schering Pharma600